Cutaneous AbscessMANAGEMENT

DERMATOLOGY PRESENTATIONS · 12 SECTIONS

⚲

557 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Allergic contact dermatitis Bullous Pemphigoid Cutaneous Abscess DRESS syndrome Eczema Herpeticum Erysipelas Erythema multiforme Henoch-Schönlein purpura Herpes Zoster (Shingles)Herpetic Whitlow Hidradenitis suppurativa Paronychia Pediculosis (Lice)Pemphigus Vulgaris Pilonidal Abscess Pressure injury Psoriasis (acute flare)Psoriasis Flare Staphylococcal Scalded Skin Syndrome Stevens-Johnson Syndrome (SJS)Toxic Epidermal Necrolysis (TEN)Urticaria (acute)Warfarin-induced Skin Necrosis

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp35

Immediate priorities

›Airway, breathing, circulation assessment

›Hemodynamic instability triggers immediate action

›SBP < 90 mmHg or MAP < 65 mmHg → IV access x2, fluid resuscitation

›HR > 120 with fever → sepsis workup

›Sepsis/SIRS criteria evaluation

›Temperature > 38°C or < 36°C

›HR > 90 bpm

›RR > 24 breaths/min

›WBC > 12 x10^9/L or < 4 x10^9/L

›If septic shock criteria met, IV antibiotics within 1 hour

›Class I recommendation

›Source control (incision and drainage) as urgent procedure

Cannot-miss diagnoses

›Necrotizing fasciitis red flags requiring emergent surgical consultation

›Pain out of proportion to exam findings

›Crepitus on palpation

›Rapidly spreading erythema beyond skin-marked borders

›Dusky, necrotic skin, bullae, or hemorrhagic changes

›Systemic toxicity disproportionate to wound appearance

›Vascular pseudoaneurysm in IVDU patients

›Pulsatile mass in groin, antecubital fossa, or neck

›Doppler ultrasound mandatory before incision in these locations

›Inadvertent incision can cause life-threatening hemorrhage

Escalation triggers

›Indications for emergent surgical consultation

›Suspected necrotizing fasciitis

›Deep space infection (hand, neck, perirectal)

02History/hx67

Presentation

›Onset and progression

›Duration of swelling, erythema, and pain

›Rate of progression (hours vs days)

›Spontaneous drainage or rupture

›Inciting event

›Skin trauma, laceration, or abrasion

›Insect bite

›Ingrown hair or folliculitis

›Injection drug use (IVDU)

›Recent shaving or hair removal

›Symptom characterization

›Pain severity and quality

›Warmth and fluctuance

›Fevers, chills, or rigors

›Red streaking from lesion (lymphangitis)

Risk factors

›Host factors

›Diabetes mellitus (impaired immune response, higher recurrence)

›HIV/AIDS or other immunosuppression

›Chronic steroid use or chemotherapy

›Organ transplant recipient

›Obesity

›Exposure factors

›Prior SSTI or abscesses (strongest predictor of recurrence)

›Known MRSA colonization or prior MRSA infection

›Close-contact environments: athletes, military, incarcerated, daycare

›Injection drug use (polymicrobial flora more likely)

03Physical Exam/exam38

Vital signs

›Hemodynamic and SIRS assessment

›Temperature: fever > 38°C or hypothermia < 36°C

›Heart rate: tachycardia > 90 bpm

›Respiratory rate: tachypnea > 24 breaths/min

›Blood pressure: hypotension SBP < 90 mmHg

›Oxygen saturation baseline

Local wound assessment

›Visual inspection

›Erythema: extent and borders (mark with skin marker to track progression)

›Swelling and edema

›Pointing or pustule formation

›Spontaneous drainage character (purulent, serosanguinous)

›Skin necrosis, dusky discoloration, or bullae

›Lymphangitic streaking (red streaking)

›Palpation

›Fluctuance: hallmark finding of abscess

›Warmth and tenderness

›Induration

›Crepitus: suggests gas-forming organism or necrotizing fasciitis

›Pulsatility: suggests pseudoaneurysm (IVDU)

›Central punctum: suggests epidermoid cyst

›Size documentation

›Measure diameter in cm

›Size > 5 cm historically associated with higher hospitalization risk in children

Regional assessment

›Lymphadenopathy

›Regional lymph node enlargement and tenderness

04Differential Diagnosis/ddx43

Infectious differentials

›Cellulitis without abscess

›ICD-10: L03.x

›No fluctuance on exam; POCUS differentiates (cobblestone pattern)

›Managed with antibiotics, not drainage

›Necrotizing fasciitis

›ICD-10: M72.6

›Cannot-miss diagnosis; requires emergent surgical debridement

›LRINEC score > 6 raises concern

›Septic arthritis

›ICD-10: M00.x

›Joint pain and swelling with erythema overlying joint

›Osteomyelitis

›ICD-10: M86.x

›Underlying bone infection especially in diabetic foot or children

›Pilonidal abscess

›ICD-10: L05.01

›Sacrococcygeal location; hair-containing sinus tract

›Bartholin gland abscess

›ICD-10: N75.1

›Vulvar location; gland-specific drainage approach

Non-infectious differentials

›Inflamed epidermoid cyst

›ICD-10: L72.0

›Central punctum present; cheesy keratinous material

›Foreign-body reaction, not true infection in many cases

›Hidradenitis suppurativa

›ICD-10: L73.2

05Laboratory Tests/lt34

Routine labs

›Uncomplicated abscess labs

›Labs generally unnecessary for uncomplicated superficial abscess

›IDSA guideline: routine labs not required before I&D in healthy adults

›Wound culture

›Gram stain and culture of purulent drainage recommended by IDSA

›Treatment without culture reasonable in typical cases (Class IIa)

›Culture critical for recurrent infections or treatment failure

›MRSA prevalence ~49% of S. aureus isolates in community-acquired SSTIs

Systemic infection labs

›Complete blood count

›Leukocytosis > 12 x10^9/L or leukopenia < 4 x10^9/L indicates SIRS

›Neutrophilia with left shift suggests bacterial infection

›Order when: SIRS criteria, immunocompromised host, large/deep abscess

›Basic metabolic panel

›Renal function required before starting TMP-SMX (dose adjustment)

›Glucose: hyperglycemia in diabetic patients

›Sodium: hyponatremia in LRINEC score for necrotizing fasciitis

›Blood cultures

›Indications: SIRS/sepsis, immunocompromised, concern for endocarditis (IVDU)

›2 sets from separate sites before antibiotic administration

›Inflammatory markers

›Lactate: obtain if sepsis suspected; lactate > 2 mmol/L = cryptic sepsis

›CRP/ESR: elevated in deep or complicated infections (LRINEC uses CRP)

›CRP > 150 mg/L in LRINEC score raises necrotizing fasciitis concern

Special circumstance labs

›IVDU-associated abscess

›Blood cultures (bacteremia and endocarditis risk)

06Diagnostic Tests/dt69

Scoring Systems

›LRINEC score (Laboratory Risk Indicator for Necrotizing Fasciitis)

›Indications: suspected necrotizing fasciitis vs complex abscess/cellulitis

›Components scored

›CRP > 150 mg/L: 4 points

›WBC 15-25 x10^9/L: 1 point; > 25: 2 points

›Hemoglobin 110-135 g/L: 1 point; < 110: 2 points

›Sodium < 135 mmol/L: 2 points

›Creatinine > 141 umol/L: 2 points

›Glucose > 10 mmol/L: 1 point

›Score interpretation

›< 6: low risk (< 50% probability necrotizing fasciitis)

›6-7: moderate risk (~50-75% probability)

›> 8: high risk (> 75% probability); emergent surgical consultation

›Limitation: sensitivity 68-80%; cannot rule out NF with low score alone

›IDSA Severity Classification for SSTI

›Mild: no SIRS criteria; I&D alone sufficient

›Moderate: SIRS criteria present; I&D + oral antibiotics with MRSA activity

›Severe: SIRS + hypotension or immunocompromised; IV antibiotics + admission

MRI

›MRI indications for cutaneous abscess

›Rarely needed for superficial abscess; reserved for deep or complex cases

›Spinal epidural abscess: back pain with fever, neurologic symptoms

›Deep fascial plane infections when CT is equivocal

›Orbital or periorbital abscess to determine surgical approach

›MRI technique

›T2 and STIR sequences: hyperintense fluid collection

›Gadolinium-enhanced T1: rim enhancement of abscess wall

›Fascial plane edema or thickening suggests deeper infection

›MRI performance

›Superior soft tissue resolution compared to CT

›Identifies deep tissue extension and fascial plane involvement

›Limitation: time-consuming; not appropriate for hemodynamically unstable patient

›CT indications

›Deep or complex abscesses (perirectal, retroperitoneal, neck)

›Concern for necrotizing fasciitis (gas in soft tissues)

›Imaging when physical exam equivocal and POCUS unavailable

›Pre-operative planning for surgical drainage

›CT technique

›CT with IV contrast preferred for abscess evaluation

›Rim-enhancing fluid collection = abscess

›Gas within soft tissues = gas-forming organisms or necrotizing fasciitis

›CT performance

›Gas in fascial planes on CT highly specific for necrotizing fasciitis

›Sensitivity for necrotizing fasciitis approximately 90%

›Limitation: radiation exposure; may miss early fascial involvement

›CT findings in abscess

›Low-attenuation fluid collection with peripheral enhancement

›Surrounding fat stranding and edema

›Loculations visible on CT may alter drainage approach

Ultrasound

›POCUS for soft tissue abscess

›First-line imaging modality in emergency department

›ACEP guideline: POCUS recommended for evaluation of skin and soft tissue infections (2023)

›Sensitivity 94.6% for abscess diagnosis (Gottlieb et al., Annals EM 2020)

›Specificity 85.4% for abscess vs cellulitis differentiation

›Changes management in approximately 10% of cases

›POCUS technique

›High-frequency linear transducer (7.5-15 MHz)

›Abscess appearance: hypoechoic or anechoic collection with internal debris

›Posterior acoustic enhancement posterior to fluid collection

›Squish sign: fluid movement with probe pressure confirms liquid content

›Cellulitis appearance: cobblestone pattern without discrete fluid collection

›POCUS applications beyond diagnosis

›Loculation identification (alters drainage strategy)

›Abscess depth and margin delineation

›Nearby vasculature mapping

›Color Doppler to rule out pseudoaneurysm before incision in high-risk locations

›POCUS limitations

›Operator dependent

›Deep abscesses may exceed ultrasound penetration depth

›Cannot reliably image fascial planes in suspected necrotizing fasciitis

07Disposition/dispo35

Discharge criteria

›Criteria for safe discharge

›Uncomplicated abscess successfully drained

›No SIRS criteria or systemic toxicity after I&D

›Hemodynamically stable after procedure

›Able to tolerate oral antibiotics if indicated

›Reliable follow-up available within 48-72 hours

›No concern for deeper space infection or necrotizing fasciitis

Admission criteria

›Indications for hospital admission

›SIRS with hypotension or septic shock

›Failed outpatient I&D or worsening despite antibiotics

›Significant immunocompromise with systemic signs

›Abscess requiring operative drainage (large, deep, or complex)

›High-risk locations: hand, face, perirectal requiring surgical management

›Concern for necrotizing fasciitis or deep space infection

›Inability to tolerate oral medications

›Unreliable follow-up or social circumstances precluding outpatient care

Specialist consultation triggers

›Surgical consultation indications

›Hand abscess (flexor tenosynovitis concern)

›Facial abscess with orbital or intracranial spread concern

›Perianal or perirectal abscess with systemic toxicity

›Suspected necrotizing fasciitis (emergent)

›Pseudoaneurysm suspected in IVDU patient

›Infectious disease consultation

›Recurrent MRSA infections despite appropriate treatment

›Atypical organisms (mycobacteria, fungi)

08Treatment/t82

Incision and drainage

›I&D as primary treatment

›Cornerstone of cutaneous abscess management (Class I recommendation)

›Curative alone for most uncomplicated abscesses

›Needle aspiration not recommended as definitive treatment (26% success vs 80% I&D)

›Anesthesia for I&D

›Local anesthesia

›Lidocaine 1-2% with or without epinephrine (avoid epinephrine in digits, tip of nose, penis)

›Field block around abscess margin preferred over intralesional injection into infected tissue

›Maximum lidocaine dose 4.5 mg/kg without epinephrine; 7 mg/kg with epinephrine

›Procedural sedation considerations

›Large abscesses in sensitive areas (face, genitalia)

›Pediatric patients

›High-anxiety patients

›I&D procedure steps

›Incision along skin tension lines for optimal cosmesis

›Incision length sufficient for complete drainage

›Blunt dissection to break up loculations (hemostat)

›Cavity irrigation with normal saline

›Packing decision

›Routine packing not recommended by current evidence

›Packing increases pain without improving outcomes

›Simple dry dressing preferred over routine packing

›Culture collection from expressed pus recommended by IDSA

›Loop drainage technique (alternative)

›Two small stab incisions with vessel loop threaded through cavity

›Preferred in pediatric patients

›Less painful, avoids packing, comparable efficacy

›Allows outpatient loop removal after 7-10 days

Adjunctive antibiotics

›Antibiotic indications post-I&D

›Mild, uncomplicated (no SIRS): no antibiotics required after I&D alone

›Moderate (SIRS criteria present): oral antibiotics with MRSA activity for 7-10 days

›Severe (SIRS + hypotension or immunocompromised): IV antibiotics

›Evidence base: Daum et al. NEJM 2017 — TMP-SMX and clindamycin improved cure rates over placebo (81.7% and 83.1% vs 68.9%) when added to I&D for abscesses ≤ 5 cm

›Preferred oral antibiotic: TMP-SMX

›TMP-SMX DS (160/800 mg) 1-2 tablets PO BID x 7-10 days

›First-line for MRSA coverage

›Cautions: hypersensitivity reactions, hyperkalemia risk, renal dose adjustment required

›Avoid in severe sulfa allergy or glucose-6-phosphate dehydrogenase deficiency

›Renal dosing: CrCl 15-30 mL/min: reduce by 50%; CrCl < 15: avoid

›Alternative oral antibiotic: clindamycin

›Clindamycin 300-450 mg PO TID x 7-10 days

›Higher adverse event rate but lower recurrence in Daum trial

›Caution: Clostridioides difficile infection risk

›Inducible clindamycin resistance: check D-zone test if MLSB phenotype

›Alternative oral antibiotic: doxycycline

›Doxycycline 100 mg PO BID x 7-10 days

›Avoid in children < 8 years (dental discoloration)

›Take with food to reduce GI adverse effects

›Contraindicated/low-yield antibiotic

›Cephalexin alone inadequate for MRSA-positive abscesses

›Higher treatment failure and repeat I&D rates vs TMP-SMX or clindamycin

›IV antibiotic therapy for severe infection

›Vancomycin IV

›15-20 mg/kg IV q8-12h (based on actual body weight)

›AUC-guided dosing preferred over trough monitoring

›Target AUC/MIC 400-600 mg·h/L

›Renal function monitoring required

›Daptomycin IV

›4-6 mg/kg IV q24h

›Alternative for MRSA or vancomycin-intolerant patients

›Monitor CPK (myopathy risk)

›Linezolid IV/PO

›600 mg IV or PO q12h

›Serotonin syndrome risk with concurrent serotonergic medications

›Maximum 28 days due to myelosuppression risk

Recurrence prevention

›Decolonization protocol (5-day course)

›Intranasal mupirocin ointment BID x 5 days

›Applied to nares bilaterally

›Targets S. aureus nasal colonization

›Daily chlorhexidine wash x 5-14 days

›Whole-body wash including hair

›Alternative: dilute bleach bath (1/4 to 1/2 cup bleach per full bath)

›Decontamination of personal items

›Towels, razors, sheets washed in hot water

›Razors disposed of or not shared

›Household contact decolonization

›Household contacts included in decolonization when recurrent household transmission

›IDSA recommendation: decolonization of close contacts for recurrent MRSA

›Behavioral counseling

›Frequent handwashing

›Avoid sharing personal hygiene items

›Glycemic optimization in diabetic patients reduces recurrence risk

09Special Populations/sp53

Pregnancy

›Physiologic considerations

›Immunologic changes of pregnancy may alter presentation and healing

›Elevated baseline heart rate and white cell count may obscure SIRS criteria

›Fetal exposure risk for all antibiotics must be considered

›Treatment modifications in pregnancy

›I&D remains first-line and is safe in pregnancy

›Local anesthesia: lidocaine safe in all trimesters (Category B)

›Antibiotic safety profile

›TMP-SMX: avoid in first trimester (folate antagonist; neural tube defect risk) and at term (neonatal hyperbilirubinemia and kernicterus risk)

›Clindamycin: generally safe in pregnancy (Category B); preferred alternative

›Doxycycline: contraindicated in pregnancy (Category D; fetal bone/dental effects)

›Vancomycin: use with caution; ototoxicity and nephrotoxicity risk; fetal safety not fully established

›Monitoring

›Fetal monitoring if systemically unwell or septic

›Obstetrics consultation for sepsis in pregnancy

›Glycemic control optimization especially in gestational diabetes

Geriatric

›Physiologic considerations

›Blunted febrile response: lower threshold for concern (temperature > 37.8°C)

›Baseline leukocytosis absent in many elderly despite infection

›Atypical presentation: confusion, functional decline, falls as presenting symptoms

›Reduced renal function affects antibiotic dosing

›Treatment modifications in elderly

›TMP-SMX: dose reduction required with CrCl < 30 mL/min

›Monitor potassium (hyperkalemia risk increased with ACE inhibitors/ARBs)

›Vancomycin: increased nephrotoxicity risk; AUC-guided dosing essential

›Clindamycin: increased C. difficile risk in elderly patients

10Background/b50

Epidemiology

›Incidence and prevalence

›Cutaneous abscess is one of the most common skin and soft tissue infections presenting to the ED

›Emergency department visits for SSTIs increased significantly in the 2000s coinciding with community-associated MRSA emergence

›Estimated 14.2 million ambulatory care visits for SSTIs annually in the US

›Pathogen distribution

›S. aureus isolated in approximately 67% of cutaneous abscesses

›MRSA specifically isolated in approximately 49% of community-acquired abscesses (Singer and Talan, NEJM 2014)

›IVDU-associated abscesses: polymicrobial with streptococci and anaerobes more common

›Atypical pathogens: mycobacteria, fungi in immunocompromised or post-travel presentations

›Recurrence rates

›Recurrence rates range from 7-45% depending on risk factors and population

›Prior SSTI is the strongest predictor of recurrence

›Household transmission clusters documented in athletic, military, and correctional settings

Pathophysiology

›Abscess formation mechanism

›Breach in skin barrier allows bacterial entry into dermis or subcutaneous tissue

›Bacterial proliferation triggers neutrophil recruitment and localized inflammatory response

›Liquefactive necrosis creates central pus-filled cavity

›Fibrous wall forms around collection (abscess capsule)

›Surrounding tissue edema and erythema from inflammatory mediators

›MRSA pathogenesis

›Community-associated MRSA strains (typically USA300) carry Panton-Valentine leukocidin (PVL)

›PVL toxin lyses neutrophils, promoting abscess formation and tissue destruction

›S. aureus nasal and skin colonization precedes most SSTIs

›Biofilm formation facilitates recurrence and antibiotic tolerance

›IVDU-specific pathophysiology

›Skin flora contamination during injection introduces diverse organisms

11Patient Discharge Instructions/pdi35

copy discharge instructions

›What is a skin abscess?

›A skin abscess is a pocket of pus under the skin caused by a bacterial infection

›The most common cause is Staphylococcus aureus, including MRSA (a resistant type)

›Treatment involves draining the pus (incision and drainage) and sometimes antibiotics

›Wound care after drainage

›Keep the wound clean and dry; change dressings as instructed by your doctor

›If a wick or packing was placed, follow instructions for removal (typically 48-72 hours)

›Warm compresses may help with residual induration and discomfort

›Do not squeeze or manipulate the wound

›Antibiotic instructions (if prescribed)

›Take antibiotics exactly as prescribed for the full course even if feeling better

›Common side effects: nausea, diarrhea — take TMP-SMX with food and plenty of water

›Contact us if severe diarrhea, rash, or allergic reaction develops

›Expected recovery

›Most uncomplicated abscesses heal within 1-2 weeks after adequate drainage

›Some redness and tenderness is expected for several days

›Return for wound check in 48-72 hours as instructed

›Return to emergency department immediately if

›Worsening redness, swelling, or pain despite treatment

›Fever above 38°C (100.4°F) or chills

›Red streaking spreading from the wound

›Wound not improving or worsening after 48 hours of treatment

›Feeling generally unwell, confused, or very weak

›New drainage from the wound that looks different or smells bad

›Prevent recurrence

›Wash hands frequently with soap and water

›Do not share towels, razors, or personal hygiene items

12References/r16

Guidelines and key sources

›Primary guidelines

›Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the IDSA. Clinical Infectious Diseases. 2014. doi:10.1093/cid/ciu296

›ACEP Ultrasound Guidelines: Emergency, Point-of-Care, and Clinical Ultrasound Guidelines in Medicine. American College of Emergency Physicians. 2023

›Landmark trials

›Singer AJ, Talan DA. Management of Skin Abscesses in the Era of Methicillin-Resistant Staphylococcus aureus. NEJM. 2014. doi:10.1056/NEJMra1212788

›Daum RS, Miller LG, Immergluck L, et al. A Placebo-Controlled Trial of Antibiotics for Smaller Skin Abscesses. NEJM. 2017. doi:10.1056/NEJMoa1607033

›Systematic reviews and meta-analyses

›Gottlieb M, Avila J, Chottiner M, Peksa GD. Point-of-Care Ultrasonography for the Diagnosis of Skin and Soft Tissue Abscesses: A Systematic Review and Meta-Analysis. Annals of Emergency Medicine. 2020. PMID: 32081383

›Long B, Gottlieb M. Diagnosis and Management of Cellulitis and Abscess in the Emergency Department Setting: An Evidence-Based Review. J Emerg Med. 2022. PMID: 34657784

›Menegas S, Moayedi S, Torres M. Abscess Management: An Evidence-Based Review for Emergency Medicine Clinicians. J Emerg Med. 2021. PMID: 33298356

›Additional references

›Jeffers K, Keim SM, Long B, Gottlieb M, Adhikari SR. Point-of-Care Ultrasound for Diagnosis of Soft Tissue Abscess vs Cellulitis. J Emerg Med. 2025. PMID: 40274497

›Robinson AL, Boyle MG, Hogan PG, et al. Evaluating Personal and Environmental Decolonization Strategies for Children With SSTI. Clin Infect Dis. 2025. PMID: 41276461

›Jenkins TC, Knepper BC, Moore SJ, et al. Microbiology and Initial Antibiotic Therapy for Injection Drug Users and Non-Injection Drug Users With Cutaneous Abscesses. Acad Emerg Med. 2015. PMID: 26202847

›Toschi A, Giannella M, Viale P. Recurrence of Skin and Soft Tissue Infections: Identifying Risk Factors and Treatment Strategies. Curr Opin Infect Dis. 2025. PMID: 39882704

›Mersal M, Embaby O, Ayyad M, et al. Beyond the Knife: A Contemporary Review of Subcutaneous Abscesses. ANZ J Surg. 2025. PMID: 41420370

Learn More: Cutaneous Abscess→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.